KR920019341A - 피부 투과성 조성물 - Google Patents

피부 투과성 조성물 Download PDF

Info

Publication number
KR920019341A
KR920019341A KR1019920006147A KR920006147A KR920019341A KR 920019341 A KR920019341 A KR 920019341A KR 1019920006147 A KR1019920006147 A KR 1019920006147A KR 920006147 A KR920006147 A KR 920006147A KR 920019341 A KR920019341 A KR 920019341A
Authority
KR
South Korea
Prior art keywords
propyl
phenyl
methyl
composition
propynylamine
Prior art date
Application number
KR1019920006147A
Other languages
English (en)
Other versions
KR950008766B1 (ko
Inventor
지.자보 아나
자보 네 우젤리 가브리엘라
토트 안탈
쥐쯔 타마스
막야르 칼만
렝겔 요제프
핀테르 야노스
젤켈리 아나
제궤 안드라스
마마로지 네 켈너 카탈린
Original Assignee
기울라 스쥬크.타마스 스주트
치노인 기오기스제르-에스 베기에스제티 테르메케크 기아라 알티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 기울라 스쥬크.타마스 스주트, 치노인 기오기스제르-에스 베기에스제티 테르메케크 기아라 알티 filed Critical 기울라 스쥬크.타마스 스주트
Publication of KR920019341A publication Critical patent/KR920019341A/ko
Application granted granted Critical
Publication of KR950008766B1 publication Critical patent/KR950008766B1/ko

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1274Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

내용 없음

Description

피부 투과성 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (3)

  1. 20~100% 이수성 액상 결정배열 내에, 5~15W.%의 광학적으로 작용하거나 라세미화 된 N-메틸-N-(페닐-2-프로필)-2-프로피닐아민, 또는 N-메틸-N-(1-(4-플르오르-페닐)-2-프로필)-2-프로리닐아민 또는 그들의 치료적으로 적절한 염, 40~70W.%의 액상 폴리옥시에틸렌, 10~20W.%의 고체상 폴리옥시에틸렌, 2~30W.%의 비이온성 표면 작용제, 2~20W.%의 프로필렌글리콜(필요시) 0.5~2W.%의 0.5~2W.%의 a값이 0.6 보다 큰 중합체와 유화제로서, 100W.%로 되는데 필요한 양의 보조제가 사용되는 것을 포함하는 탈수 피부 투과성 조성물.
  2. 혼합물내에, 40~70W.%의 액상 폴리옥시에틸렌과 10~20W.%의 고체상 폴리옥시에틸렌, 2~30W.%의 비이온성 표면 작용제, 2~20W.%의 프로필렌글리콜이 5~15W.%의 광학적으로 작용하거나 라세미화된 N-메틸-N-(페닐-2-프로필)-2-프로피닐아민 또는 N-메틸-N-(1-(4-플르오르-페닐)-2-프로필)-2-프로리닐아민 또는 액상 결정 배열의 이수성 조성물을 조제하는 데 치료적으로 적합한 그들의 염이 함께 주입되고, 필요시 0.5~2.0W.%의 a값이 0.6보다 큰 중합체와 100W.%가 되는데 필요한 양의 다른 보조제가 첨가된 조성물과 관련된 것을 특징으로 하는 탈수 피부투과성 조성물의 제조방법.
  3. 5~15W.%의 광학적으로 작용하거나 라세미화된 N-메틸-N-(페닐-2-프로필)-2-프로피닐아민 또는 N-메틸-N-(1-(4-플르오르-페닐)-2-프로필)-2-프로리닐아민 또는 그들의 치료적으로 적합한 염이 특징이 되어 효능을 증가시키기 위해 작용성분이 피부표면위에 20~100W.%의 이수성 액상 결정 조성물의 형태로 이용되어지는 것으로 된 피부 투과성 조성물의 제조방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019920006147A 1991-04-15 1992-04-13 피부투과성 조성물 KR950008766B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU911229A HU209605B (en) 1991-04-15 1991-04-15 Process for production of wather-free transdermal preparation
HU1229/91 1991-04-15

Publications (2)

Publication Number Publication Date
KR920019341A true KR920019341A (ko) 1992-11-19
KR950008766B1 KR950008766B1 (ko) 1995-08-08

Family

ID=10953442

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920006147A KR950008766B1 (ko) 1991-04-15 1992-04-13 피부투과성 조성물

Country Status (35)

Country Link
US (1) US5380761A (ko)
EP (1) EP0509761B1 (ko)
JP (1) JP2547151B2 (ko)
KR (1) KR950008766B1 (ko)
AT (1) ATE142486T1 (ko)
AU (1) AU648886B2 (ko)
BG (1) BG61637B1 (ko)
CA (1) CA2065134A1 (ko)
CZ (1) CZ281261B6 (ko)
DE (1) DE69213536T2 (ko)
DK (1) DK0509761T3 (ko)
EC (1) ECSP920873A (ko)
EE (1) EE03038B1 (ko)
ES (1) ES2092031T3 (ko)
FI (1) FI101677B1 (ko)
GR (1) GR3021505T3 (ko)
HK (1) HK1003977A1 (ko)
HR (1) HRP920570A2 (ko)
HU (2) HU209605B (ko)
IE (1) IE921019A1 (ko)
IL (1) IL101487A (ko)
LT (1) LT3044B (ko)
LV (1) LV10044B (ko)
MX (1) MX9201732A (ko)
NO (1) NO303903B1 (ko)
NZ (1) NZ242335A (ko)
PH (1) PH29992A (ko)
PL (1) PL173234B1 (ko)
RO (1) RO109603B1 (ko)
RU (1) RU2088617C1 (ko)
SK (1) SK278666B6 (ko)
TW (1) TW198690B (ko)
UA (1) UA26892C2 (ko)
YU (1) YU48552B (ko)
ZA (1) ZA922355B (ko)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6313176B1 (en) 1989-10-17 2001-11-06 Everett J. Ellinwood, Jr. Dosing method of administering deprenyl via intraoral administration or inhalation administration
HUT63579A (en) * 1991-12-20 1993-09-28 Chinoin Gyogyszer Es Vegyeszet Process for producing double-phase pharmaceutical compositions suitable for treating diseases occurring during neurodegenerative processes
AU679937B2 (en) * 1992-11-18 1997-07-17 Johnson & Johnson Consumer Products, Inc. Extrudable compositions for topical or transdermal drug delivery
US5817336A (en) * 1993-04-02 1998-10-06 Orion-Yhtyma Oy Composition containing selegiline
US6033682A (en) 1995-01-13 2000-03-07 Somerset Pharmaceuticals, Inc. S(+) desmethylselegiline and its use in therapeutic methods and pharmaceutical compositions
US6319954B1 (en) 1995-01-13 2001-11-20 Somerset Pharmaceuticals, Inc. S-(+)-desmethylselegiline and its use in the therapeutic methods and pharmaceutical compositions
US6348208B1 (en) * 1995-01-13 2002-02-19 Somerset Pharmaceuticals, Inc. Methods and pharmaceutical compositions employing desmethylselegiline
US6299901B1 (en) 1995-01-13 2001-10-09 Somerset Pharmaceuticals, Inc. Methods and pharmaceutical compositions employing desmethylselegiline
WO1996040085A2 (en) 1995-06-07 1996-12-19 Noven Pharmaceuticals, Inc. Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
US6316022B1 (en) 1995-06-07 2001-11-13 Noven Pharmaceuticals, Inc. Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
HUP9601442A3 (en) * 1995-07-25 1999-03-29 Panacea Biotec Ltd Nes antinflammatory and analgetic pharmaceutical compositions, containing nimesulid for transdermal use, and process for producing them
WO1998052560A1 (en) 1997-05-21 1998-11-26 Sloan-Kettering Institute For Cancer Research Method for increasing the concentration of ascorbic acid in brain tissues of a subject
US6262111B1 (en) 1997-05-21 2001-07-17 Sloan-Kettering Institute For Cancer Research Method for increasing the concentration of ascorbic acid in brain tissues of a subject
US7150881B2 (en) 1997-06-26 2006-12-19 Mylan Technologies, Inc. Adhesive mixture for transdermal delivery of highly plasticizing drugs
DE19743323C2 (de) * 1997-09-30 2000-05-25 Iip Inst Fuer Ind Pharmazie Fo Feste Arzneimittelzusammensetzung auf der Grundlage von Selegilin
IL138290A0 (en) 1998-03-16 2001-10-31 Somerset Pharmaceuticals Inc Use of selegiline or desmethylselegiline for treating wounds, burns and dermatological damage
DE19814257A1 (de) * 1998-03-31 1999-10-07 Asta Medica Ag Brauseformulierungen
US6316469B1 (en) 2000-03-01 2001-11-13 Duke University Use of selective serotonin reuptake inhibitors for treatment of chest pain of non-cardiac origin and gastro-esophageal reflux disease
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
US20030087814A1 (en) 2001-11-05 2003-05-08 Seth Lederman Compositions and methods for increasing compliance with therapies using aldehyde dehydrogenase inhibitors and treating alcoholism
US20040018237A1 (en) 2002-05-31 2004-01-29 Perricone Nicholas V. Topical drug delivery using phosphatidylcholine
US8435942B2 (en) * 2002-05-31 2013-05-07 Transdermal Biotechnology, Inc. Methods for formulating stabilized insulin compositions
IL152486A0 (en) * 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US7645803B2 (en) * 2005-05-09 2010-01-12 Foamix Ltd. Saccharide foamable compositions
US20070292355A1 (en) * 2002-10-25 2007-12-20 Foamix Ltd. Anti-infection augmentation foamable compositions and kit and uses thereof
US9265725B2 (en) * 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US20070292359A1 (en) * 2002-10-25 2007-12-20 Foamix Ltd. Polypropylene glycol foamable vehicle and pharmaceutical compositions thereof
US8119109B2 (en) * 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US8486376B2 (en) * 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US20050205086A1 (en) * 2002-10-25 2005-09-22 Foamix Ltd. Retinoid immunomodulating kit and composition and uses thereof
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US20080206161A1 (en) * 2002-10-25 2008-08-28 Dov Tamarkin Quiescent foamable compositions, steroids, kits and uses thereof
US10117812B2 (en) * 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US7700076B2 (en) 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
US20050271596A1 (en) * 2002-10-25 2005-12-08 Foamix Ltd. Vasoactive kit and composition and uses thereof
US20050186142A1 (en) * 2002-10-25 2005-08-25 Foamix Ltd. Kit and composition of imidazole with enhanced bioavailability
US7704518B2 (en) * 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
MXPA05004278A (es) * 2002-10-25 2005-10-05 Foamix Ltd Espuma cosmetica y farmaceutica.
US20080317679A1 (en) * 2002-10-25 2008-12-25 Foamix Ltd. Foamable compositions and kits comprising one or more of a channel agent, a cholinergic agent, a nitric oxide donor, and related agents and their uses
US20060193789A1 (en) * 2002-10-25 2006-08-31 Foamix Ltd. Film forming foamable composition
US20080138296A1 (en) 2002-10-25 2008-06-12 Foamix Ltd. Foam prepared from nanoemulsions and uses
US20060018937A1 (en) * 2002-10-25 2006-01-26 Foamix Ltd. Steroid kit and foamable composition and uses thereof
US8119150B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Non-flammable insecticide composition and uses thereof
US7820145B2 (en) * 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US7575739B2 (en) 2003-04-28 2009-08-18 Foamix Ltd. Foamable iodine composition
US8486374B2 (en) * 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
HUP0303313A2 (hu) * 2003-10-09 2005-07-28 Richter Gedeon Vegyészeti Gyár Rt. Transzdermális gyógyszerkészítmények
TW200716193A (en) * 2005-04-28 2007-05-01 Japan Science & Tech Agency Skin regeneration promoter
US20080152596A1 (en) * 2005-07-19 2008-06-26 Foamix Ltd. Polypropylene glycol foamable vehicle and pharmaceutical compositions thereof
WO2008032212A2 (en) * 2006-09-08 2008-03-20 Foamix Ltd. Colored or colorable foamable composition and foam
US20080206155A1 (en) * 2006-11-14 2008-08-28 Foamix Ltd. Stable non-alcoholic foamable pharmaceutical emulsion compositions with an unctuous emollient and their uses
US20080260655A1 (en) 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
DE102007014286A1 (de) * 2007-03-19 2008-09-25 Universität Tübingen Fluorsubstituierte Amphetamine und Amphetaminderivate und deren Verwendung
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US20090130029A1 (en) * 2007-11-21 2009-05-21 Foamix Ltd. Glycerol ethers vehicle and pharmaceutical compositions thereof
WO2009069006A2 (en) 2007-11-30 2009-06-04 Foamix Ltd. Foam containing benzoyl peroxide
WO2009072007A2 (en) * 2007-12-07 2009-06-11 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
WO2010041141A2 (en) 2008-10-07 2010-04-15 Foamix Ltd. Oil-based foamable carriers and formulations
EP2242476A2 (en) * 2008-01-14 2010-10-27 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
US20120087872A1 (en) 2009-04-28 2012-04-12 Foamix Ltd. Foamable Vehicles and Pharmaceutical Compositions Comprising Aprotic Polar Solvents and Uses Thereof
WO2011013009A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
WO2011013008A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
MX359879B (es) 2009-10-02 2018-10-12 Foamix Pharmaceuticals Ltd Composiciones tópicas de tetraciclina.
JP5619438B2 (ja) * 2010-03-12 2014-11-05 株式会社フジモト・コーポレーション セレギリン含有貼付製剤
JP2014508166A (ja) 2011-03-17 2014-04-03 トランスダーマル バイオテクノロジ インコーポレーテッド 局所的一酸化窒素システム及びその使用方法
US8871261B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Cancer treatments and compositions for use thereof
US8871259B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Techniques and systems for treatment of neuropathic pain and other indications
US8871256B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Methods and systems for treatment of inflammatory diseases with nitric oxide
US8871260B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Methods and compositions for muscular and neuromuscular diseases
US8871255B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Treatment of skin and soft tissue infection with nitric oxide
US8871254B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Systems and methods for treatment of acne vulgaris and other conditions with a topical nitric oxide delivery system
US8871262B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Compositions and methods for treatment of osteoporosis and other indications
US8871258B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Treatment and prevention of learning and memory disorders
US8871257B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Prevention and treatment of cardiovascular diseases using systems and methods for transdermal nitric oxide delivery
US9387159B2 (en) 2013-03-13 2016-07-12 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9295647B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9314423B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Hair treatment systems and methods using peptides and other compositions
US9339457B2 (en) 2013-03-13 2016-05-17 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9314422B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9393265B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9849160B2 (en) 2013-03-13 2017-12-26 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9295636B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9320706B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US20140271731A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9750787B2 (en) 2013-03-13 2017-09-05 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9724419B2 (en) 2013-03-13 2017-08-08 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9295637B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Compositions and methods for affecting mood states
US20140271937A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9241899B2 (en) 2013-03-13 2016-01-26 Transdermal Biotechnology, Inc. Topical systems and methods for treating sexual dysfunction
US9314417B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9320758B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9687520B2 (en) 2013-03-13 2017-06-27 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9393264B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9314433B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US20140271938A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US11160753B2 (en) 2015-03-02 2021-11-02 Medlab Clinical U.S., Inc. Transmucosal and transdermal delivery systems
US10398641B2 (en) 2016-09-08 2019-09-03 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US468218A (en) 1892-02-02 Door-securer
HU187775B (en) * 1982-07-14 1986-02-28 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu New process for producing propargile-amines of pharmaceutical activity
US4861800A (en) * 1987-08-18 1989-08-29 Buyske Donald A Method for administering the drug deprenyl so as to minimize the danger of side effects
US4868218A (en) * 1987-08-18 1989-09-19 Buyske Donald A Method of treating depression
IL88099A (en) * 1987-11-06 1992-02-16 Chinoin Gyogyszer Es Vegyeszet Lyotropic liquid crystalline compositions
GB8807504D0 (en) * 1988-03-29 1988-05-05 Sandoz Ltd Improvements in/relating to organic compounds
WO1990001298A1 (en) 1988-07-29 1990-02-22 Michelson Gary K Improved spinal retractor
US5053227A (en) * 1989-03-22 1991-10-01 Cygnus Therapeutic Systems Skin permeation enhancer compositions, and methods and transdermal systems associated therewith

Also Published As

Publication number Publication date
HUT63560A (en) 1993-09-28
NO921481L (no) 1992-10-16
NO921481D0 (no) 1992-04-14
HRP920570A2 (en) 1994-08-31
DE69213536T2 (de) 1997-03-20
PL173234B1 (pl) 1998-02-27
JPH06128152A (ja) 1994-05-10
RO109603B1 (ro) 1995-04-28
CZ281261B6 (cs) 1996-07-17
HK1003977A1 (en) 1998-11-13
IL101487A0 (en) 1992-12-30
US5380761A (en) 1995-01-10
FI921690A (fi) 1992-10-16
YU48552B (sh) 1998-11-05
IL101487A (en) 1996-01-19
DE69213536D1 (de) 1996-10-17
FI101677B (fi) 1998-08-14
EP0509761B1 (en) 1996-09-11
NZ242335A (en) 1994-06-27
ZA922355B (en) 1992-12-30
TW198690B (ko) 1993-01-21
EP0509761A1 (en) 1992-10-21
EE03038B1 (et) 1997-10-15
CA2065134A1 (en) 1992-10-16
KR950008766B1 (ko) 1995-08-08
CS111092A3 (en) 1992-11-18
RU2088617C1 (ru) 1997-08-27
AU648886B2 (en) 1994-05-05
LTIP176A (lt) 1994-03-25
NO303903B1 (no) 1998-09-21
SK278666B6 (en) 1997-12-10
PL294240A1 (en) 1993-09-20
JP2547151B2 (ja) 1996-10-23
LT3044B (en) 1994-09-25
DK0509761T3 (ko) 1997-02-17
FI101677B1 (fi) 1998-08-14
HU211544A9 (en) 1995-12-28
IE921019A1 (en) 1992-10-21
MX9201732A (es) 1992-10-01
LV10044A (lv) 1994-05-10
BG61637B1 (bg) 1998-02-27
UA26892C2 (uk) 1999-12-29
ES2092031T3 (es) 1996-11-16
ECSP920873A (es) 1994-02-02
PH29992A (en) 1996-10-29
LV10044B (en) 1995-02-20
GR3021505T3 (en) 1997-01-31
YU38492A (sh) 1995-03-27
FI921690A0 (fi) 1992-04-15
HU209605B (en) 1994-09-28
AU1484992A (en) 1992-10-22
ATE142486T1 (de) 1996-09-15
HU911229D0 (en) 1991-10-28

Similar Documents

Publication Publication Date Title
KR920019341A (ko) 피부 투과성 조성물
TR200103493T2 (tr) Metaloproteaz önleyicileri
CR7614A (es) Preparaciones de insulina acida con estabilidad mejorada
WO2001077107B1 (en) Oxazole derivatives and their uses as tyrosine kinase inhibitors
BR0008405A (pt) Composição de fator viii formulada sem a adição de albumina, uso de uma composição de fator viii, e, método de liofilizar uma formulação farmacêutica aquosa
GR1003711B (el) Μεθοδος δια την παρασκευη φαρμακευτικων συνθεσεων δια συστηματικην διαδερμικην χορηγησιν.
WO2002040021A3 (en) Methods for inhibiting the transmission of hiv using topically applied substituted 6-benzyl-4-oxopyrimidines
DK0722313T3 (da) Viskoelastiske sammensætninger af fluorerede organiske forbindelser
WO1999055332A8 (fr) Compositions medicinales
IT1264857B1 (it) Composizione farmaceutica liquida per uso orale contenente acido 2-(4-isobutilfenil) propionico
SE9202066L (sv) Prokaterol-haltigt preparat foer paafoering paa huden
MY111055A (en) Pharmaceutical composition and process for the preparation thereof
AU2001278708A1 (en) Adenosine derivatives and use thereof
DE60104670D1 (de) Verwendung einer lacrophyl zubereitung in augentropfen, die therapeutisch wirksame komponenten enthalten
ATE83668T1 (de) Pflaster zur transdermalen anwendung.
DK316682A (da) Fremgangsmaade til fremstilling af optisk aktive dipeptider
YU47871B (sh) Derivati aminokiselina
UY23489A1 (es) Procedimiento para la elaboracion de una preparacion transdermica.-

Legal Events

Date Code Title Description
A201 Request for examination
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 19990615

Year of fee payment: 5

LAPS Lapse due to unpaid annual fee